<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819570</url>
  </required_header>
  <id_info>
    <org_study_id>0149-15-NHR</org_study_id>
    <nct_id>NCT02819570</nct_id>
  </id_info>
  <brief_title>Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes</brief_title>
  <official_title>Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Galilee Hospital-Nahariya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Galilee Hospital-Nahariya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare a new antibiotic protocol with the current
      prophylactic treatment in routine use and to evaluate obstetric and neonatal outcome: preterm
      labor, chorioamnionitis and early onset sepsis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm premature rupture of membranes (PPROM) occurs in approximately 3% of all pregnancies
      and is associated with approximately one-third of preterm births. The incidence of
      chorioamnionitis in women with premature rupture of membranes (PROM) at &lt; 27, 28 to 36, and &gt;
      37weeks' gestation is 41, 15, and 2%, respectively. Intra-amniotic infection is usually
      polymicrobial, comprised vaginal or enteric flora including aerobic and anaerobic bacteria
      and atypical agents, such as Mycoplasma. Group B streptococcus (GBS) has been a frequent
      pathogen. The American College of Obstetricians and Gynecologists approach to PPROM consists
      of recommending induction of labor in all women &gt; 34 weeks' gestation. In the absence of
      intrauterine infection, placental abruption or non-reassuring fetal heart rate, management of
      women with PPROM &lt; 34 weeks consists of hospitalization from the time of diagnosis until
      delivery, administration of antenatal corticosteroids, and a 7-day course of antibiotic
      prophylactic therapy to prolong the latency period. Antibiotic therapy has been associated
      with significant reductions in chorioamnionitis, deliveries within 48 hours, and early-onset
      (within 3 days of delivery) neonatal sepsis (EOS). The antibiotic regimen in PPROM usually
      consists of ampicillin intravenously for 48 hours, followed by oral amoxicillin for 5 days
      (specifically targeting GBS), and a macrolide targeting atypical agents.

      An increase in EOS due to gram negative Enterobacteriaceae have been reported lately with a
      relative decrease in GBS related EOS . These data may have an impact on the antibiotic
      regimen used for PPROM. The Local pathogens distribution in cases of EOS and their antibiotic
      sensitivity profiles in Northern Israel have been explored in a multicenter study There were
      27 neonates diagnosed with EOS with positive blood cultures. Aerobic Enterobacteriaceae
      accounted for 14 cases (52%) and group B streptococcus for 7 cases (26%). Of the Escherichia
      coli and Klebsiella sp.,only 38% were sensitive to ampicillin. As a result the most effective
      antibiotic protocol to cover those pathogens is required. The purpose of the current study is
      to compare a new antibiotic protocol with the current prophylactic treatment in use and to
      evaluate pregnancy and neonatal outcome.

      The diagnosis of preterm premature rupture of membranes (PPROM) is clinical, and is based on
      visualization of amniotic fluid in the vagina of a woman who presents with a history of
      leaking fluid. Laboratory tests as &quot;Amniosure&quot; can be used to confirm the clinical diagnosis
      when it is uncertain.

      Women who meet the study criteria and have signed inform consent will be randomly divided in
      two groups to receive prophylactic antibiotic treatment as follow:

        1. I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for additional
           5 days+ P.O roxithromycin 150 mg*2/d for 7 days

        2. I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d + P.O
           roxithromycin 150 mg*2/d for 7 days

      A course of corticosteroids will be given to all women participating in the study

      Expectant management:

        1. Vital signs *3/day

        2. Uterine tenderness evaluation

        3. Complete Blood Count + C-reactive protein every second day

        4. Urine culture and GBS recto-vaginal swab

        5. Fetal heart monitoring*6 /d

        6. Sonography evaluation every 2-3 days

        7. Vaginal swab once a week

        8. Fetal movements follow up

      Labor induction will be conducted at 34 weeks of gestation If chorioamnionitis is suspected
      amniocentesis should be considered or expeditious delivery
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EARLY NEONATAL SEPSIS - positive blood culture</measure>
    <time_frame>within 3 days of delivery</time_frame>
    <description>Number of Participants with early neonatal sepsis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>latency period</measure>
    <time_frame>from date of randomization until the date of delivery assessed up to 10 weeks</time_frame>
    <description>time in days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chorioamnionitis rate</measure>
    <time_frame>from day of randomization until date of clinical/laboratory chorioamnionitis diagnosis assessed up to 10 weeks</time_frame>
    <description>rate of positive cultures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonatal weight</measure>
    <time_frame>at delivery</time_frame>
    <description>grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>1 minute 5 minute</time_frame>
    <description>score from 0 to 10</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events as assessed by umbilical cord acid-based analysis&lt;7</measure>
    <time_frame>at delivery</time_frame>
    <description>cord ph analysis at delivery (units of moles per liter)</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal intensive care unit (NICU) admission duration</measure>
    <time_frame>days since delivery until rerelease from NICU, assessed up to 6 month</time_frame>
    <description>days from admission until rerelease from NICU assessed up to 6 month</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Premature Rupture of Membrane</condition>
  <arm_group>
    <arm_group_label>cefuroxime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg*2/d for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ampicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg*2/d for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I.V cefuroxime 750 mg*3/d for 2 days</intervention_name>
    <arm_group_label>cefuroxime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I.V ampicillin 2 gram x4/d for 2 days</intervention_name>
    <arm_group_label>ampicillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P.O cefuroxime 500 mgx2/d for 5 days</intervention_name>
    <arm_group_label>cefuroxime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P.O roxithromycin 150 mg*2/d for 7 days</intervention_name>
    <arm_group_label>cefuroxime</arm_group_label>
    <arm_group_label>ampicillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P.O moxypen 500 mgx3/d for 5 days</intervention_name>
    <arm_group_label>ampicillin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with PPROM between 24+0 and 34+0 weeks of gestation who are suitable for
             conservative management

        Exclusion Criteria:

          -  P-PROM&gt;34 weeks of gestation

          -  Suspected fetal distress or chorioamnionitis

          -  Active labor

          -  Drug allergy to one of the study regiments

          -  Immune deficiency

          -  Multiple pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1Department of Obstetrics &amp; Gynecology, Galilee Medical Center, 2Faculty of Medicine in the Galilee, Bar Ilan University, Nahariya, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya Wolf, MD</last_name>
    <phone>972-507887800</phone>
    <email>homesickid@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Galil Medical Center</name>
      <address>
        <city>Nahariyya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Wolf, MD</last_name>
      <phone>972-507887800</phone>
      <email>homesickid@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet Gynecol Clin North Am. 2005 Sep;32(3):411-28. Review.</citation>
    <PMID>16125041</PMID>
  </reference>
  <reference>
    <citation>Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol. 1993 Dec;36(4):795-808. Review.</citation>
    <PMID>8293582</PMID>
  </reference>
  <reference>
    <citation>Sperling RS, Newton E, Gibbs RS. Intraamniotic infection in low-birth-weight infants. J Infect Dis. 1988 Jan;157(1):113-7.</citation>
    <PMID>3335795</PMID>
  </reference>
  <reference>
    <citation>Practice bulletins No. 139: premature rupture of membranes. Obstet Gynecol. 2013 Oct;122(4):918-30. doi: 10.1097/01.AOG.0000435415.21944.8f.</citation>
    <PMID>24084566</PMID>
  </reference>
  <reference>
    <citation>Carlan SJ, O'Brien WF, Parsons MT, Lense JJ. Preterm premature rupture of membranes: a randomized study of home versus hospital management. Obstet Gynecol. 1993 Jan;81(1):61-4.</citation>
    <PMID>8416463</PMID>
  </reference>
  <reference>
    <citation>Turnbull DA, Wilkinson C, Gerard K, Shanahan M, Ryan P, Griffith EC, Kruzins G, Stamp GE. Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women. Lancet. 2004 Apr 3;363(9415):1104-9.</citation>
    <PMID>15064028</PMID>
  </reference>
  <reference>
    <citation>Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004454. Review. Update in: Cochrane Database Syst Rev. 2017 Mar 21;3:CD004454.</citation>
    <PMID>16856047</PMID>
  </reference>
  <reference>
    <citation>Harding JE, Pang J, Knight DB, Liggins GC. Do antenatal corticosteroids help in the setting of preterm rupture of membranes? Am J Obstet Gynecol. 2001 Jan;184(2):131-9.</citation>
    <PMID>11174492</PMID>
  </reference>
  <reference>
    <citation>Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2013 Dec 2;(12):CD001058. doi: 10.1002/14651858.CD001058.pub3. Review.</citation>
    <PMID>24297389</PMID>
  </reference>
  <reference>
    <citation>Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD, Rabello YA, Meis PJ, Moawad AH, Iams JD, Van Dorsten JP, Paul RH, Bottoms SF, Merenstein G, Thom EA, Roberts JM, McNellis D. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA. 1997 Sep 24;278(12):989-95.</citation>
    <PMID>9307346</PMID>
  </reference>
  <reference>
    <citation>Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010 Dec 17;59(RR-12):1-110. Erratum in: MMWR Recomm Rep. 2011 Jan 14;60(1):18. Dosage error in article text.</citation>
    <PMID>21160459</PMID>
  </reference>
  <reference>
    <citation>Grigsby PL, Novy MJ, Sadowsky DW, Morgan TK, Long M, Acosta E, Duffy LB, Waites KB. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol. 2012 Dec;207(6):475.e1-475.e14. doi: 10.1016/j.ajog.2012.10.871. Epub 2012 Oct 23.</citation>
    <PMID>23111115</PMID>
  </reference>
  <reference>
    <citation>Wolf MF, Miron D, Peleg D, Rechnitzer H, Portnov I, Salim R, Keness Y, Reich D, Ami MB, Peretz A, Koshnir A, Shachar IB. Reconsidering the Current Preterm Premature Rupture of Membranes Antibiotic Prophylactic Protocol. Am J Perinatol. 2015 Nov;32(13):1247-50. doi: 10.1055/s-0035-1552935. Epub 2015 May 29.</citation>
    <PMID>26023907</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Galilee Hospital-Nahariya</investigator_affiliation>
    <investigator_full_name>Dr. Maya Wolf</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>early-onset neonatal sepsis</keyword>
  <keyword>Prophylactic antibiotics</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>PPROM</keyword>
  <keyword>EOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
    <mesh_term>Roxithromycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

